Galván-Díaz CA, Cárdenas-Cardós R, Rojas-Maruri CM, Palma-Rosillo RM, Aguilar-Ortiz MR

Idioma: Español
Referencias bibliográficas: 15
Paginas: 222-227
Archivo PDF: 1512.97 Kb.

FRAGMENTO

Niño de 7 años 6 meses de edad, con historia de cuatro meses de evolución caracterizada por constipación nasal, epistaxis y rinorrea amarillenta bilateral; fiebre no cuantificada de predominio nocturno y pérdida de peso no cuantificada. Estos síntomas se presentaban al menos una vez por semana de manera continua. Examen físico: aumento de volumen de la región malar derecha y el párpado inferior ipsi-lateral, con dolor a la palpación; adenomegalias bilaterales cervicales y sub-mandibulares con diámetro de 0.5 a 1 cm de consistencia blanda. Una radiografía posteroanterior de tórax no mostró masa mediastinal.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Fisher MJ, Rheingold SR. Oncologic Emergencies. In: Principles and Practice of Pediatric Oncology, 6th, Pizzo PA, Poplack DG (Eds), Lippincott Williams and Wilkins, Philadelphia 2011. p.1125.

2. Walji N, Chan AK, Peake DR. Common acute oncological emergencies: diagnosis, investigation and management. Postgrad Med J. 2008;84:418–427.

3. Wilson LD, Detterbeck FC, Yahalom J. Superior vena cava syndrome with malignant causes. N Engl JMed. 2007;356:1862–1869.

4. Ben-Ari J, Schonfeld T, Harlev E, Steinberg R, Yaniv I, Katz J, Schwartz M, Freud E. Life threatenin gairway obstruction secondary to mass in children – a preventable event? Pediatric Emergency Care. 2005;21(7):427–430.

5. Cairo, M.S., Coiffier, B., Reiter, A. and Younes, A. Recommendations for the evaluation ofrisk and prophylaxis of tumor lysis syndrome (TLS) in adults and children with malignant disease: an expert TLS panel consensus. British Journal of Hematology. 2010;149; 578–586.

6. Coiffier B, Altman A, Pui C-H.and Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. Journal of Clinical Oncology. 2008;26(16):2767–2778.

7. Sonis ST. A biological approach to mucositis. J Support Oncol. 2004; 2:21–32.

8. Lalla RV, Sonis ST, Peterson DE Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008:52;61–77.

9. Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45:1296.

10. Mendes A, Sapolnik R, Mendonca N. New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients. Jornal de Pediatria. 2007;83(2):S54.

11. Lehrnbecher T, Foster C, Vazquez N et al. Therapy induced alterations in host defense in children receiving therapy for cancer. J Pediatr Hematol Onco. 1997;l19:399–417.

12. Phillips RS, Wade R, Lehrnbecher T et al. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med. 2012;10:6.

13. Hughes W, Armstrong D, Bodey G, Bow E, Brown A, et al. Guide lines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. CID. 2002;34:730–751.

14. Ramphal R, Grant RM, Dzolganovski B, et al. Herpes simplex virus in febrile neutropenic children undergoing chemotherapy for cancer: a prospective cohort study. Pediatr Infect Dis J. 2007;26:700.

15. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guide lines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453.